Abstract:This work focuses on the δ receptor (DOR), a G protein-coupled receptor (GPCR) belonging to the opioid receptor group. DOR is expressed in numerous tissues, particularly within the nervous system. Our study explores computationally the receptor's interactions with various ligands, including opiates and opioid peptides. It elucidates how these interactions influence the δ receptor response, relevant in a wide range of health and pathological processes. Thus, our investigation aims to explore the significance of DOR as an incoming drug target for pain relief and neurodegenerative diseases and as a source for novel opioid non-narcotic analgesic alternatives. We analyze the receptor's structural properties and interactions using Molecular Dynamics (MD) simulations and Gaussian-accelerated MD across different functional states. To thoroughly assess the primary differences in the structural and conformational ensembles across our different simulated systems, we initiated our study with 1 μs of conventional Molecular Dynamics. The strategy was chosen to encompass the full activation cycle of GPCRs, as activation processes typically occur within this microsecond range. Following the cMD, we extended our study with an additional 100 ns of Gaussian accelerated Molecular Dynamics (GaMD) to enhance the sampling of conformational states. This simulation approach allowed us to capture a comprehensive range of dynamic interactions and conformational changes that are crucial for GPCR activation as influenced by different ligands. Our study includes comparing agonist and antagonist complexes to uncover the collective patterns of their functional states, regarding activation, blocking, and inactivation of DOR, starting from experimental data. In addition, we also explored interactions between agonist and antagonist molecules from opiate and opioid classifications to establish robust structure-activity relationships. These interactions have been systematically quantified using a Quantitative Structure-Activity Relationships (QSAR) model. This research significantly contributes to our understanding of this significant pharmacological target, which is emerging as an attractive subject for drug development.

Design, Synthesis, and Characterization of New δ Opioid Receptor-Selective Fluorescent Probes and Applications in Single-Molecule Microscopy of Wild-Type Receptors

Structural Basis for Bifunctional Peptide Recognition at Human Δ-Opioid Receptor

Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.

Design, Syntheses, and Pharmacological Characterization of 17-Cyclopropylmethyl-3,14 Beta-Dihydroxy-4,5 Alpha-Epoxy-6 Alpha-(Isoquinoline-3 '-Carboxamido)morphinan Analogues As Opioid Receptor Ligands

Identification of 1,3,8-Triazaspiro[4.5]Decane-2,4-Dione Derivatives as a Novel δ Opioid Receptor-Selective Agonist Chemotype

Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists

Descriptive molecular pharmacology of the δ opioid receptor (DOR): A computational study with structural approach

Design, synthesis, and biological evaluation of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as μ opioid receptor selective Antagonists

Design and Synthesis of a Bivalent Probe Targeting the Putative Mu Opioid Receptor and Chemokine Receptor CXCR4 Heterodimer

In silico design of novel probes for the atypical opioid receptor MRGPRX2

Application of Bivalent Bioisostere Concept on Design and Discovery of Potent Opioid Receptor Modulators

Single-molecule detection of transient dimerization of opioid receptors 1: Homodimers' effect on signaling and internalization

Design, synthesis, and biological evaluation of 14-heteroaromatic-substituted naltrexone derivatives: pharmacological profile switch from mu opioid receptor selectivity to mu/kappa opioid receptor dual selectivity.

Homology modeling and molecular dynamics simulations of the mu opioid receptor in a membrane-aqueous system.

Discovery of Potent and Selective Agonists of Δ Opioid Receptor by Revisiting the "Message-Address" Concept.

Structure activity relationship studies of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan (NAQ) analogues as potent opioid receptor ligands: preliminary results on the role of electronic characteristics for affinity and function.

Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives As Μ/κ Opioid Receptor Dual Selective Ligands.

Characterization of 6α- and 6β-N-heterocyclic substituted naltrexamine derivatives as novel leads to development of mu opioid receptor selective antagonists.

Elucidating the active δ-opioid receptor crystal structure with peptide and small-molecule agonists

Structure activity relationship studies of 6α- and 6β-indolylacetamidonaltrexamine derivatives as bitopic mu opioid receptor modulators and elaboration of the 'message-address concept' to comprehend their functional conversion.

Molecular Modeling on Kappa Opioid Receptor and Its Interaction with Nonpeptide Kappa Opioid Agonists